CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 33 enrolled
Drug / intervention
Sofosbuvir +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02939989
NCT02939989Phase 3Completed
CompareCT.gov

An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Combination With Sofosbuvir and Ribavirin in Chronic Hepatitis C (HCV) Infected Subjects Who Have Experienced Virologic Failure in AbbVie HCV Clinical Studies (MAGELLAN-3)

AbbVie·interventional·Posted Oct 20, 2016·Updated May 4, 2022

In Brief

A Phase 3 clinical trial evaluating Sofosbuvir, Glecaprevir/Pibrentasvir, and 1 other intervention for Hepatitis C Virus Infection. Completed, enrolled 33 participants across 26 sites in 12 countries.

Detailed Summary

The purpose of this study was to evaluate the efficacy and safety of co-administration of glecaprevir (ABT-493)/pibrentasvir (ABT 530) plus sofosbuvir (SOF) plus ribavirin (RBV) in hepatitis C virus (HCV) genotype (GT) 1 - 6-infected participants (including non-cirrhotic, or cirrhotic with compensated cirrhosis participants) who had experienced virologic failure in an AbbVie parent clinical study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C Virus Infection
CountriesAustralia, Canada, China, Germany, New Zealand, Russia, South Korea, Spain, Sweden, Switzerland, United Kingdom, United States
Collaborators--

Timeline

Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedOct 20, 2016
Enrollment StartNov 21, 2016
Primary CompletionMay 7, 2021
Study CompletionJul 30, 2021
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 9.7 years ago

Interventions

Sofosbuvirdrug

Tablet for oral administration

Glecaprevir/Pibrentasvirdrug

Coformulated tablet for oral administration

Ribavirindrug

Tablet for oral administration